

LEVEL III

## ASKLEPIOS Course

# INTRODUCTION TO HYBRID IMAGING IN ONCOLOGY

August 30-31, 2018  
Vienna/Austria



This ASKLEPIOS course is implemented with great support and partnership of ESHIMT (European Society for Hybrid, Molecular and Translational Imaging).

*Education in partnership.*

LEVEL III

# ASKLEPIOS Course

## INTRODUCTION TO HYBRID IMAGING IN ONCOLOGY

August 30-31, 2018  
Vienna/Austria

### Course information

This course is aimed at final-year residents, general radiologists, nuclear medicine physicians and oncologists who want to update their knowledge on new applications and state-of-the-art hybrid medical imaging of cancer. No previous practical experience of the subject is required. The expert faculty comprises nuclear medicine physicians and radiologists who will provide a series of lectures describing optimal imaging pathways for oncological diagnosis, follow-up and response assessment. Lectures will be followed by workshops allowing for interactive case discussions.

### Learning objectives

- to learn the principles of hybrid medical imaging
- to learn the key clinical questions at different points in the patient's journey
- to understand the indications, limitations and comparative merits of each part in hybrid medical imaging in a wide range of oncologic conditions and how it relates to other modalities
- to appreciate the complementary roles of structural and functional/molecular imaging in cancer management
- to understand hybrid medical imaging pathways for a range of different tumour types including lung cancer, head and neck, prostate and gynaecological cancer
- to understand how information derived from imaging guides patient selection for treatment and supports individualised treatment planning



# Programme

## INTRODUCTION TO HYBRID IMAGING IN ONCOLOGY

August 30-31, 2018  
Vienna/Austria

### Thursday, August 30, 2018

13:00-13:45	Registration
13:45-14:00	Welcome and introduction
14:00-14:30	<b>The basics of hybrid imaging</b> T. Beyer, Vienna/AT
14:30-15:00	<b>Hybrid imaging in head and neck cancer</b> M. Becker, Geneva/CH
15:00-15:30	<b>PET CT in lung cancer</b> K. Riklund, Umeå/SE
15:30-15:50	Coffee break
15:50-18:00	<b>Workshops</b> (T. Beyer, M. Becker, K. Riklund)

### Host Organisers



**K. Riklund**  
Umeå/SE



**C. Herold**  
Vienna/AT

### Friday, August 31, 2018

09:00-09:30	<b>Cardiac MRI/PET</b> M. Gutberlet, Leipzig/DE
09:30-10:00	<b>Hybrid imaging in haematological disorders</b> M. Mayerhöfer, Vienna/AT
10:00-10:30	<b>Hybrid imaging in prostate cancer</b> H.-P. Schlemmer, Heidelberg/DE
10:30-10:50	Coffee break
10:50-13:00	<b>Workshops</b> (M. Gutberlet, M. Mayerhöfer, H.-P. Schlemmer)
13:00-14:00	Lunch break
14:00-14:30	<b>Hybrid imaging in gynaecological cancer</b> A. Rockall, London/UK
14:30-15:00	<b>Hybrid imaging in paediatric oncology</b> S. Gatidis, Tuebingen/DE
15:00-15:30	<b>MRI PET present and future</b> G. Antoch, Essen/DE
15:30-15:50	Coffee break
15:50-18:00	<b>Workshops</b> (A. Rockall, S. Gatidis, G. Antoch)
18:00	Certificate of attendance

### Venue

Tech Gate Vienna  
Donau-City-Straße 1  
1220 Vienna  
Austria

### Registration fee

ESR members in training  
Early fee EUR 200; Late fee EUR 250

Non-members in training  
Early fee EUR 300; Late fee EUR 350

ESR members  
Early fee EUR 300; Late fee EUR 350

Non-members  
Early fee EUR 400; Late fee EUR 450

(Early fee until eight weeks prior to the course)  
(Late fee after eight weeks prior to the course)

Registration fees are inclusive 10% VAT.



This ASKLEPIOS course is implemented with great support and partnership of ESHI<sup>MT</sup> (European Society for Hybrid, Molecular and Translational Imaging).

LEVEL III

## Learning Objectives

# INTRODUCTION TO HYBRID IMAGING IN ONCOLOGY

August 30-31, 2018  
Vienna/Austria

### The basics of hybrid imaging

T. Beyer, Vienna/AT

- to understand what is hybrid imaging
- to discuss why hybrid imaging is better than standalone imaging
- to learn what a radiotracer is and why it is not a contrast agent
- to discuss where hybrid imaging (SPECT/CT, PET/CT, PET/MR) will take us

### Hybrid imaging in head and neck cancer

M. Becker, Geneva/CH

- to describe the rationale, advantages and disadvantages of cross-sectional imaging techniques for the evaluation of head and neck squamous cell carcinoma
- to learn to plan an optimal imaging approach depending on the individual clinical situation
- to identify potential pitfalls and limitations of image interpretation and how to avoid them
- to provide a detailed radiologic report enabling correct treatment decisions

### PET CT in lung cancer

K. Riklund, Umeå/SE

- to understand the importance of an accurate staging in lung cancer patients
- to appreciate the strengths and weaknesses of hybrid imaging in lung cancer staging
- to become familiar with the most important pitfalls in lung cancer staging

### Hybrid imaging in haematological disorders

M. Mayerhöfer, Vienna/AT

- to understand the influence of lymphoma histology on [18F]FDG uptake on PET
- to learn the current Lugano and RECIL criteria for treatment response assessment in lymphoma patients
- to understand the current limitations of CT, MRI, and [18F]FDG-PET/CT in lymphomas
- to understand the roles of CT, MRI and [18F]FDG-PET for imaging of myeloma
- to become familiar with novel PET tracers and their potential use in haematological malignancies

### Hybrid imaging in prostate cancer

H.-P. Schlemmer, Heidelberg/DE

- to understand the key clinical issues of prostate cancer management and the essential role of imaging
- to learn how multiparametric MRI should be performed and interpreted in a standardised manner according to international PI-RADS guidelines
- to appreciate the strengths of TRUS/MR fusion-guided biopsy in the clinical context
- to become familiar with the complementary roles of MR and PET for tumour detection, staging and personalised therapy

# Learning Objectives

## INTRODUCTION TO HYBRID IMAGING IN ONCOLOGY

August 30-31, 2018  
Vienna/Austria

### Hybrid imaging in gynaecological cancer

A. Rockall, London/UK

- to understand the optimal role and the limitations of FDG-PET/CT in gynaecological cancer
- to know the pitfalls on PET imaging that can readily be avoided by joint review with MRI
- to know the key advantages of combining PET information with MRI
- to learn about new tracers being developed for use in gynaecologic cancer

### Hybrid imaging in paediatric oncology

S. Gatidis, Tuebingen/DE

- to know basic technical aspects of PET/CT and PET/MR with respect to paediatric imaging: choice of tracer, tracer dosage, CT and MRI protocols, dose exposure, patient preparation
- to know the main indications for the use of hybrid imaging in paediatric oncology
- to know the main differences between PET/CT and PET/MR with respect to diagnostic information and indications
- to know specifics and pitfalls in reading whole body PET/CT and PET/MR examinations in paediatric oncology

### MRI PET present and future

G. Antoch, Essen/DE

- to learn about the current status and future perspectives of PET/MRI
- to learn about indications of PET/MRI in oncology
- to be able to define clinically relevant imaging protocols



Please note that programmes are marked with a logo to indicate their classification according to the European Training Curriculum.

**LEVEL I** First three years of training

**LEVEL II** Fourth and fifth year of training  
(general radiologist standard)

**LEVEL III** Subspecialty training standard

**ESOR stands for education in partnership.**

This ASKLEPIOS Course is implemented with great support and partnership of ESHI<sup>MT</sup> (European Society for Hybrid, Molecular and Translational Imaging).

